Bafna Pharmaceuticals Peer Comparison

Bafna Pharmaceuticals Ltd. significantly lags behind its peers in key financial metrics, including revenue growth, profitability, and efficiency. Its negative ROE and high PE ratio indicate financial distress, making it a risky investment compared to stronger competitors in the pharmaceuticals sector.

• • Bafna Pharmaceuticals has the lowest revenue growth, EPS, ROA, ROE, and EBITDA margin among peers.
• • Sun Pharmaceutical Industries and Cipla Ltd. stand out as strong performers with robust growth and profitability metrics.
• • Bafna Pharmaceuticals has a concerning debt-equity ratio which indicates financial instability.

• • Cipla Ltd.: Leading in profitability with a PE of 23.73, ROE of 16.63%, and solid revenue growth of 13.28% YoY.
• • Sun Pharmaceutical Industries Ltd.: Strong revenue growth (8.42% YoY) and profitability metrics (ROE of 16.13%), though it has a high PE of 87.59.
• • Dr. Reddy's Laboratories Ltd.: Strong overall metrics with a low PE (15.50) and high profitability (ROE of 21.76%).